Despite the government's vow to boost the nation's biotech industry, the focus on a quick return may not be feasible for a sector that requires long-term commitment and effort, an industry veteran told the Taipei Times yesterday.
"I think Taiwan is doing the right thing [boosting its biotech industry]," Stefan Ziegler, general manager of Novartis Taiwan Co, said on the sidelines of a forum held by his company in Taipei yesterday.
The government has put a lot of effort into increasing investment in biomedical research and catching up with advanced countries in this field, Ziegler said.
Expectation for short-term returns, however, is an issue that the government and the industry have to address, as the sector requires long-term commitment, he said, noting that the research and development of the drug Gleevec, which entered the market in 2000, began in the 1960s.
Waiting for results from the money-burning R&D process may not be inspiring to local venture investors.
"Life science research and industry development requires time, but investors also need incentives [to invest]," said Lai Por-hsiung (賴博雄), president of President Life Sciences Co (統一生命科技), one of the speakers at the forum.
Investors seeking quick returns could raise the proportion of their investment in divisions such as medical devices, Lai said.
With capitalization of US$100 million, President Life Sciences, the biotech venture-capital arm of Uni-President Group (統一企業集團), has 40 percent of its money invested in biotech, 30 percent in herbal medicine and pharmaceuticals and the rest in medical technology.
"Investment in research oriented fields, such as gene therapy and molecular diagnostics, cannot be reaped quickly and thus may not be so appealing to local investors ? but they are beneficial to Taiwan's long-term development," said Johnsee Lee (李鍾熙), president of the semi-official Industrial Technology Research Institute (工研院), another speaker at the forum.
Since these fields are more related to pharmaceutical companies than end users, the nation could take advantage of its skilled personnel and lower research costs to become a R&D hub for overseas pharmacists, Lee said.
Minister of Economic Affairs Ho Mei-hsueh (何美玥) said on Wednesday that the government would target new drug development and medical devices in its efforts to promote the biotech industry, which is included in the "Two Trillion, Twin Star" investment plan, along with semiconductors, flat-panel displays and the digital-content industries.
The biotech industry generated NT$131.6 billion in revenues last year, with NT$61.4 coming from pharmaceuticals, NT$40.6 billion from medical devices and the rest from new biotechnology, according to the Biotechnology and Pharmaceutical Industries Program Office.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts